S100A7A and lung cancer: However, we estimated the power to be 87% for the comparison of real time RT-PCR S100A15 gene expression levels in PBMC between the patients with NSCLC and the HC, and 95% for the comparison of nuclear S100A15 total immunostaining scores in lung cancer tissues between stage IIIB and IV patients using a two-sided Mann-Whitney test, and assuming that the actual distribution was logistic with a simple adjustment to the sample size in our study and an α error of 0.05 with PASS 2005 (NCSS, Kaysville, Utah, USA) software.